Pediatric Crohn disease (CD), which can have serious impacts on children’s growth, is increasing in incidence. Current treatments for pediatric patients with CD—such as corticosteroids or immunomodulators—may be particularly difficult for children to tolerate. Infliximab, however, has been shown to be effective and well tolerated in children, as a newly published phase 3 study in Japanese pediatric patients with CD found that infliximab improved clinical outcome measures from week 2 to week 56.
Pediatric Crohn disease (CD), which can have serious impacts on children’s growth, is increasing in incidence. Current treatments for pediatric patients with CD—such as corticosteroids or immunomodulators—may be particularly difficult for children to tolerate. Infliximab, however, has been shown to be effective and well tolerated in children, as a newly published phase 3 study in Japanese pediatric patients with CD found that infliximab improved clinical outcome measures from week 2 to week 56.
The open-label, uncontrolled, multicenter phase 3 study, conducted at 9 sites between 2012 and 2015, enrolled 14 patients, aged 6 to 17 years. All of the patients had CD and an inadequate response to other therapies. All patients received 5 mg/kg of infliximab at weeks 0, 2, and 6, followed by 8-week administration intervals until week 46. The 5 patients who had inadequate responses as measured by the Pediatric Crohn’s Disease Activity Index (PCDAI) after week 14 received dose escalations to 10 mg/kg. One patient in the 5-mg group discontinued treatment after being identified as having a surgical indication for fistulas.
Click to read more about using biologics to treat pediatric patients.
The median (interquartile range) PCDAI score decreased from 35.0 at baseline to 13.75 (10.0-17.5) at week 2, 10.0 (5.0-10.0) at week 6, and 5.0 (0.0-12.5) at week 10, then ranged from 0.0 to 10.0 from week 14 to week 54. The overall median PCDAI score at week 54 was 6.25 (0.00-20.0), the PCDAI response rate at week 54 was 85.7%, and the overall remission rate at week 54 was 64.3%. For patients whose doses were escalated, by 8 weeks after the dose increase, PCDAI response rates and remission rates were both 60.0%.
Notably, 2 of 3 patients who had used corticosteroids at baseline were able to withdraw from steroid treatment, and both achieved remission. Withdrawal from steroids is an important objective in management of CD in children because of their potential to inhibit growth.
All of the patients experienced adverse events (AEs), with the most common AEs being infection and infestation, and 14.3% of patients had serious AEs. No differences in safety were observed between the 5-mg and 10-mg groups.
“Administration of [infliximab] was well tolerated and rapidly improved clinical symptoms, and the effects were maintained for up to 54 weeks,” the authors concluded.
Reference
Tajiri H, Motoya S, Kinjio F, et al. Infliximab for pediatric patients with Crohn’s disease: a phase 3, open-label, uncontrolled, multicenter trial in Japan [published online August 16, 2018.] PLOS One. doi: 10.1371/journal.pone.0201956.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.